The Globe and Mail reports in its Wednesday edition that Aurora Cannabis has agreed to buy Anandia Laboratories Inc. in an all-stock deal valued at $115-million. A Canadian Press dispatch to The Globe says that Anandia provides research and development services as well as analytical testing for clients licensed under Canada's medical cannabis rules. Aurora chief executive officer Terry Booth says that the deal expands his company's capabilities and will help accelerate product development. Anandia's cannabis testing services will remain operationally independent of Aurora. Aurora has been gearing up in anticipation of the legalization of recreational marijuana in Canada expected later this year. Its shares closed Tuesday at $8.86, down six cents on the Toronto Stock Exchange.